Ingredients maker Novacap has acquired natural cosmetic ingredient producer ID bio, alongside H2B, which manufactures fractionated blood products for in vitro diagnosis.

The acquisition of ID bio is in line with Novacap’s growth strategy to widen its cosmetics offering with active and functional ingredients, with H2B developing the company’s footprint in the healthcare and pharmaceutical markets.

ID Bio is said bring expertise in enzymatic extraction and purification to develop innovative active ingredients and botanical extracts. The company focuses on ‘ethical and eco-friendly sourcing of raw materials to offer differentiated ingredients with controlled traceability.’

Pierre Luzeau, Novacap CEO, said, “ID bio and H2B’s innovation capabilities will enrich Novacap’s offering and ability to meet the needs of our customers.”

Jean-Pierre Picot, Founding President of ID Bio continued, “Novacap will support ID bio and H2B to accelerate their development leveraging the two companies’ market approaches and recognised expertise. The complementarities between our two groups open up outstanding prospects for the future.”